Sapient Capital LLC Acquires 3,794 Shares of Stryker Corporation $SYK

Sapient Capital LLC lifted its holdings in Stryker Corporation (NYSE:SYK) by 168.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,044 shares of the medical technology company’s stock after acquiring an additional 3,794 shares during the period. Sapient Capital LLC’s holdings in Stryker were worth $1,908,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Norges Bank bought a new stake in Stryker in the 4th quarter valued at about $1,822,272,000. Bank of America Corp DE bought a new position in shares of Stryker during the second quarter worth approximately $1,404,284,000. Auto Owners Insurance Co raised its position in shares of Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Stryker in the second quarter valued at approximately $707,212,000. Finally, Jupiter Topco LLC bought a new stake in shares of Stryker in the second quarter valued at approximately $681,581,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SYK. Piper Sandler reduced their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Citigroup reissued a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. Finally, Truist Financial boosted their price target on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Down 1.6%

Shares of SYK opened at $302.92 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.37. The company has a market cap of $116.19 billion, a P/E ratio of 31.39, a P/E/G ratio of 1.93 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The firm has a 50 day simple moving average of $328.84 and a two-hundred day simple moving average of $329.73.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the business posted $3.13 EPS. The company’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.